Summary

The lateral flow assays market is expected to grow from USD 9.14 billion in 2026 to USD 13.52 billion by 2031, with a CAGR of 8.1%. The high prevalence of infectious diseases worldwide and the resulting need for testing, rapid growth in the geriatric population, the rising use of home-based lateral flow assay devices, and growing demand for POC testing are the major factors driving market growth. However, inconsistent accuracy compared to other methods and reluctance among doctors and patients to shift from traditional diagnostics are restraining growth in the lateral flow assays market.

The clinical testing segment, by application, is expected to hold the largest share during the forecast period.
The clinical testing segment is the largest application segment in the lateral flow assays market. By application, the lateral flow assays market is segmented into clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing. The clinical testing segment accounted for the largest share of the lateral flow assays market in 2025. This segment's large share is attributed to the rising prevalence of chronic and infectious diseases worldwide, the growing geriatric population, increasing patient awareness of rapid test options, growing pressure to reduce healthcare costs, and increasing demand for patient-centric care.

The hospitals & clinics segment accounts for the largest market share in the lateral flow assays market.
Based on end users, the LFA market is segmented into hospitals & clinics, diagnostic laboratories, home care settings, pharmaceutical & biotechnology companies, and others. Hospitals & clinics accounted for the largest market share in 2025. Technological advancements, increasing adoption of point-of-care testing, and the growing inclination toward fast, early diagnosis are driving growth in the hospitals & clinics segment.

North America is expected to hold the largest share during the forecast period.
The global lateral flow assays market is segmented into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America leads this market, driven by advanced healthcare infrastructure, significant healthcare expenditure, and the strong presence of key manufacturers. The increasing aging population, rising prevalence of infectious and chronic diseases, and strong demand for home-use and self-test kits further support market growth in North America. This regional segment is expected to maintain its dominant position throughout the forecast period.

A breakdown of the primary participants referred to in this report is provided below:
- By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
- By Designation: C-level: 27%, Director Level: 18%, and Others: 55%
- By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%
- The major players operating in the lateral flow assays market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Siemens AG (Germany), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), Revvity, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Merck KGaA (Germany), SurModics, Inc. (US), and OraSure Technologies, Inc. (US).

Research Coverage
This report studies the lateral flow assays market based on product (kits & reagents and readers), application (clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing), technique (sandwich assays, competitive assays, and multiplex detection assays), sample type (blood samples, urine samples, saliva samples, and other samples), end user (hospitals & clinics, diagnostic laboratories, home care settings, pharmaceutical & biotechnology companies, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries). The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets by their individual growth trends. It forecasts revenue for the market segments across six major regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.

The report provides insights on the following points:
- Analysis of key drivers (high prevalence of infectious diseases, rising geriatric population, growing use of home-based lateral flow assay devices, and growing demand for POC testing), restraints (inconsistent results of lateral flow assay tests), opportunities (evolving applications of lateral flow assays and rising demand for lateral flow assays in the food & beverage industry), and challenges (limited reimbursements for lateral flow assay products and difficulties in procuring quality raw materials to develop tests)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the lateral flow assays market
- Product Development/Innovation: Detailed insights into the upcoming trends, R&D activities, and product launches in the lateral flow assays market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the lateral flow assays market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

ページTOPに戻る

Table of Contents

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 40
1.3 MARKET SCOPE 41
1.3.1 MARKETS COVERED 41
1.3.2 INCLUSIONS & EXCLUSIONS 42
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 43
1.4 STAKEHOLDERS 43
1.5 SUMMARY OF CHANGES 43

2 EXECUTIVE SUMMARY 45
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 45
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS SHAPING MARKET 47
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 47
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 48

3 PREMIUM INSIGHTS 49
3.1 LATERAL FLOW ASSAYS MARKET OVERVIEW 49
3.2 LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2026 VS. 2031 49
3.3 LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2026 VS. 2031 50
3.4 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2026 VS. 2031 50
3.5 LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2026 VS. 2031 51
3.6 LATERAL FLOW ASSAYS MARKET, BY END USER, 2026 VS. 2031 51
3.7 LATERAL FLOW ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52

4 MARKET OVERVIEW 53
4.1 INTRODUCTION 53
4.2 MARKET DYNAMICS 53
4.2.1 DRIVERS 54
4.2.1.1 High prevalence of infectious diseases 54
4.2.1.2 Rising geriatric population 55
4.2.1.3 Growing use of home-based lateral flow assay devices 56
4.2.1.4 Growing demand for point-of-care (POC) testing 56
4.2.2 RESTRAINTS 57
4.2.2.1 Inconsistent results of lateral flow assay tests 57
4.2.3 OPPORTUNITIES 57
4.2.3.1 Evolving applications of lateral flow assays 57
4.2.3.2 Rising demand for lateral flow assays in food & beverage industry 58
4.2.4 CHALLENGES 59
4.2.4.1 Limited reimbursements for lateral flow assay products 59
4.2.4.2 Difficulties in procuring quality raw materials to develop tests 59
4.3 UNMET NEEDS AND WHITE SPACES 60
4.3.1 UNMET NEEDS IN LATERAL FLOW ASSAYS MARKET 60
4.3.2 WHITE SPACE OPPORTUNITIES 60
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 61
4.4.1 INTERCONNECTED MARKETS 61
4.4.2 CROSS-SECTOR OPPORTUNITIES 62
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 63
4.5.1 KEY MOVES AND STRATEGIC FOCUS 63

5 INDUSTRY TRENDS 64
5.1 PORTER’S FIVE FORCES ANALYSIS 64
5.1.1 BARGAINING POWER OF SUPPLIERS 65
5.1.2 BARGAINING POWER OF BUYERS 65
5.1.3 THREAT OF NEW ENTRANTS 65
5.1.4 THREAT OF SUBSTITUTES 65
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.2 MACROECONOMIC INDICATORS 66
5.2.1 INTRODUCTION 66
5.2.2 GDP TRENDS AND FORECAST 66
5.3 SUPPLY CHAIN ANALYSIS 69
5.4 VALUE CHAIN ANALYSIS 70
5.5 ECOSYSTEM ANALYSIS 71
5.6 PRICING ANALYSIS 72
5.6.1 AVERAGE SELLING PRICE, BY REGION, 2024–2026 73
5.6.2 AVERAGE SELLING PRICE, BY KEY PLAYER, 2024–2026 74
5.7 TRADE ANALYSIS 74
5.7.1 IMPORT SCENARIO (HS CODE 382200) 75
5.7.2 EXPORT SCENARIO (HS CODE 382200) 75
5.8 KEY CONFERENCES & EVENTS, 2026–2027 76
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76
5.10 INVESTMENT & FUNDING SCENARIO 77
5.11 IMPACT OF 2025 US TARIFFS–LATERAL FLOW ASSAYS MARKET 78
5.11.1 INTRODUCTION 78
5.11.2 KEY TARIFF RATES 78
5.11.3 PRICE IMPACT ANALYSIS 79
5.11.4 IMPACT ON COUNTRIES/REGIONS 79
5.11.4.1 North America 79
5.11.4.2 Europe 79
5.11.4.3 Asia Pacific 79
5.11.5 IMPACT ON END-USE INDUSTRIES 80
5.11.5.1 Hospitals & clinics 80

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 81
6.1 KEY EMERGING TECHNOLOGIES 81
6.1.1 IMMUNOCHROMATOGRAPHY 81
6.2 COMPLEMENTARY TECHNOLOGIES 81
6.2.1 LYOPHILIZATION (FREEZE-DRYING) TECHNOLOGIES 81
6.3 ADJACENT TECHNOLOGIES 81
6.3.1 ELISA (ENZYME-LINKED IMMUNOSORBENT ASSAYS) 81
6.4 TECHNOLOGY/PRODUCT ROADMAP 82
6.5 PATENT ANALYSIS 83
6.5.1 LIST OF MAJOR PATENTS 84
6.6 FUTURE APPLICATIONS 85
6.7 IMPACT OF AI/GENERATIVE AI ON LATERAL FLOW ASSAYS MARKET 85
6.7.1 INTRODUCTION 85
6.7.2 TOP USE CASES AND MARKET POTENTIAL 86
6.7.3 KEY COMPANIES IMPLEMENTING AI 87
6.7.4 FUTURE OF AI 87

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 88
7.1 REGIONAL REGULATIONS AND COMPLIANCE 88
7.1.1 REGULATORY ANALYSIS 88
7.1.1.1 North America 88
7.1.1.2 Europe 88
7.1.1.3 Asia Pacific 89
7.1.1.3.1 India 89
7.1.1.3.2 China 89
7.1.1.3.3 Japan 89
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
7.1.2.1 North America 90
7.1.2.2 Europe 90
7.1.2.3 Asia Pacific 91
7.1.2.4 Latin America 91
7.1.2.5 Rest of the world 91
7.2 SUSTAINABILITY INITIATIVES 92
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN LATERAL FLOW ASSAYS MARKET 92
7.2.1.1 Eco-friendly Initiatives 92
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 93

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 95
8.1 DECISION-MAKING PROCESS 95
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 95
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 95
8.2.2 BUYING CRITERIA 96
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 97
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 98
8.5 MARKET PROFITABILITY 99
8.5.1 REVENUE POTENTIAL 99
8.5.2 COST DYNAMICS 99
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 99

9 LATERAL FLOW ASSAYS MARKET, BY PRODUCT 101
9.1 INTRODUCTION 102
9.2 KITS & REAGENTS 102
9.2.1 RISE IN DEMAND FOR POC TESTING TO DRIVE MARKET 102
9.3 READERS 105
9.3.1 DIGITAL/HANDHELD READERS 108
9.3.1.1 Technological evolutions and demand for accuracy to drive adoption 108
9.3.2 BENCHTOP READERS 111
9.3.2.1 Lower diagnosis cost per patient to drive adoption 111

10 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE 114
10.1 INTRODUCTION 115
10.2 SANDWICH ASSAYS 115
10.2.1 WIDE RANGE OF APPLICATIONS IN CLINICAL TESTING TO SUPPORT
MARKET GROWTH 115
10.3 COMPETITIVE ASSAYS 118
10.3.1 REDUCED SELECTIVITY AND SENSITIVITY COMPARED TO SANDWICH
ASSAYS TO HAMPER GROWTH 118
10.4 MULTIPLEX DETECTION ASSAYS 120
10.4.1 HIGHER ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS
TO FUEL MARKET 120

11 LATERAL FLOW ASSAYS MARKET, BY APPLICATION 123
11.1 INTRODUCTION 124
11.2 CLINICAL TESTING 124
11.2.1 INFECTIOUS DISEASE TESTING 127
11.2.1.1 Mosquito-borne diseases 129
11.2.1.1.1 Increase in incidence of dengue and introduction of more reliable test kits to drive market 129
11.2.1.2 Influenza 133
11.2.1.2.1 Rise in prevalence of influenza globally to boost market growth, despite lower sensitivity of lateral flow assays 133
11.2.1.3 Sexually transmitted infections 135
11.2.1.3.1 HIV 138
11.2.1.3.1.1 Growing need for early detection and awareness of HIV POC testing to drive market 138
11.2.1.3.2 HPV 140
11.2.1.3.2.1 Rapid HPV diagnostics and real-time PCR, covering a broad range of genotypes, coupled with the higher incidence of cervical cancer to drive segment 140
11.2.1.3.3 Chlamydia 143
11.2.1.3.3.1 Greater viability of advanced techniques to drive market 143
11.2.1.3.4 Gonorrhea 146
11.2.1.3.4.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth 146
11.2.1.3.5 Syphilis 148
11.2.1.3.5.1 Need for early and accessible diagnosis to fuel growth 148
11.2.1.3.6 Other sexually transmitted infections 151
11.2.1.4 Hepatitis 153
11.2.1.4.1 Nucleic acid hybridization-based LFAs to show strong potential in hepatitis testing 153
11.2.1.5 Tuberculosis 156
11.2.1.5.1 Rise in prevalence and growing focus on early diagnosis and treatment to propel market 156
11.2.1.6 Other infectious diseases 158
11.2.2 CARDIAC MARKER TESTING 160
11.2.2.1 Troponin I & T 163
11.2.2.1.1 Introduction of high-sensitivity troponin assays to support market growth 163
11.2.2.2 CK-MB 166
11.2.2.2.1 Growing applications of lateral flow tests in acute myocardial injuries to drive market 166
11.2.2.3 BNP & NT-proBNP 168
11.2.2.3.1 Increase in demand for cardiac biomarker tests to detect heart stress and damage to support growth 168
11.2.2.4 Myoglobin 170
11.2.2.4.1 Availability of new high-sensitivity cardiac troponin assays to restrict market growth 170
11.2.2.5 D-Dimer 172
11.2.2.5.1 Rising incidence of CVDs to drive market for D-Dimer tests 172
11.2.2.6 Other cardiac markers 174
11.2.3 PREGNANCY & FERTILITY TESTING 177
11.2.3.1 Pregnancy testing 180
11.2.3.1.1 Pregnancy testing to hold larger market share but register slower growth 180
11.2.3.2 Fertility testing 183
11.2.3.2.1 Rise in infertility rates to drive demand for POC fertility testing kits 183
11.2.4 CHOLESTEROL/LIPID TESTING 185
11.2.4.1 Lifestyle changes, cardiovascular disorder incidence to drive segment 185
11.2.5 DRUGS-OF-ABUSE TESTING 188
11.2.5.1 Technological advancements and rising focus on workplace drug testing to drive market 188
11.2.6 OTHER CLINICAL TESTS 190
11.3 VETERINARY DIAGNOSTICS 193
11.3.1 INFECTIOUS DISEASE OUTBREAKS AND TESTS AVAILABLE FOR DIFFERENT SPECIES TO DRIVE FRAGMENTED MARKET 193
11.4 FOOD SAFETY & ENVIRONMENT TESTING 195
11.4.1 HIGH SENSITIVITY AND EASE OF USE TO BOOST DEMAND FOR ASSAYS TO CLEAR FOODS FOR MARKET AVAILABILITY 195
11.5 DRUG DEVELOPMENT & QUALITY TESTING 198
11.5.1 GREATER FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO SUPPORT MARKET GROWTH 198

12 LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE 201
12.1 INTRODUCTION 202
12.2 BLOOD SAMPLES 202
12.2.1 SIGNIFICANT USE OF BLOOD SAMPLES FOR INFECTIOUS DISEASE
TESTING TO DRIVE MARKET 202
12.3 URINE SAMPLES 205
12.3.1 GROWING USE OF URINE SAMPLES FOR PREGNANCY AND DRUGS-
OF-ABUSE TESTING TO DRIVE MARKET 205
12.4 SALIVA SAMPLES 207
12.4.1 EASY AND LOW-COST COLLECTION, TRANSPORT, AND ANALYSIS OF
SALIVA SAMPLES TO SUPPORT ADOPTION 207
12.5 OTHER SAMPLES 209

13 LATERAL FLOW ASSAYS MARKET, BY END USER 212
13.1 INTRODUCTION 213
13.2 HOSPITALS & CLINICS 213
13.2.1 HIGH DEMAND FOR DIAGNOSTICS ACROSS LARGE POOLS OF
PATIENTS IN HOSPITALS TO DRIVE MARKET 213
13.3 HOME CARE SETTINGS 216
13.3.1 GROWING ACCEPTANCE OF REMOTE MONITORING TO PROPEL MARKET 216
13.4 DIAGNOSTIC LABORATORIES 218
13.4.1 LABORATORY TESTING LARGELY PREFERRED OVER PROFESSIONAL
SETTINGS FOR URINE AND BLOOD TESTING 218
13.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 221
13.5.1 RISING FOCUS ON PRODUCT SAFETY TO DRIVE ADOPTION OF LATERAL
FLOW ASSAYS 221
13.6 OTHER END USERS 223

14 LATERAL FLOW ASSAYS MARKET, BY REGION 227
14.1 INTRODUCTION 228
14.2 NORTH AMERICA 228
14.2.1 US 234
14.2.1.1 Large patient base to drive market growth 234
14.2.2 CANADA 239
14.2.2.1 Availability of research funding and implementation of favorable government initiatives to drive market 239
14.3 EUROPE 243
14.3.1 GERMANY 248
14.3.1.1 Well-developed healthcare system and rise in geriatric population
to fuel growth 248
14.3.2 UK 253
14.3.2.1 Growth in incidence of chronic conditions to propel market growth 253
14.3.3 FRANCE 257
14.3.3.1 High prevalence of age-related chronic diseases and infectious diseases to drive market 257
14.3.4 ITALY 262
14.3.4.1 Growth in initiatives toward decentralization of medical services
to support market growth 262
14.3.5 SPAIN 267
14.3.5.1 Aging population and strong healthcare infrastructure to drive market 267
14.3.6 REST OF EUROPE 271
14.4 ASIA PACIFIC 277
14.4.1 JAPAN 282
14.4.1.1 Growing elderly population and well-developed healthcare system
to drive market 282
14.4.2 CHINA 287
14.4.2.1 Modernized healthcare system to drive market 287
14.4.3 INDIA 292
14.4.3.1 Growth in healthcare concerns and rise in income levels to
propel market growth 292
14.4.4 AUSTRALIA 297
14.4.4.1 Rise in prevalence of infectious disease and healthcare expenditure to support growth 297
14.4.5 SOUTH KOREA 301
14.4.5.1 Growth in healthcare infrastructure to drive market 301
14.4.6 REST OF ASIA PACIFIC 306
14.5 LATIN AMERICA 311
14.5.1 BRAZIL 316
14.5.1.1 High private healthcare expenditure and rise in geriatric population to drive market 316
14.5.2 MEXICO 320
14.5.2.1 Efficient healthcare system and universal health coverage to
support adoption 320
14.5.3 ARGENTINA 325
14.5.3.1 Availability of health insurance to favor market growth 325
14.5.4 REST OF LATIN AMERICA 330
14.6 MIDDLE EAST & AFRICA 334
14.6.1 RISING BURDEN OF INFECTIOUS DISEASES AND GROWING
GOVERNMENT SUPPORT TO DRIVE MARKET 334
14.7 GCC COUNTRIES 339
14.7.1 RISE IN DEMAND FOR RAPID AND COST-EFFECTIVE DIAGNOSTICS
TO DRIVE MARKET 339

15 LATERAL FLOW ASSAYS MARKET: VOLUME ANALYSIS 345
15.1 INTRODUCTION 345
15.2 GLOBAL NUMBER OF NEWLY DIAGNOSED TB CASES, 2024–2031 (MILLION) 345

16 COMPETITIVE LANDSCAPE 346
16.1 INTRODUCTION 346
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 346
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LATERAL
FLOW ASSAYS MARKET 346
16.3 REVENUE ANALYSIS, 2023–2025 348
16.4 MARKET SHARE ANALYSIS, 2025 348
16.5 COMPANY VALUATION AND FINANCIAL METRICS 350
16.6 BRAND/PRODUCT COMPARISON 351
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 352
16.7.1 STARS 352
16.7.2 EMERGING LEADERS 352
16.7.3 PERVASIVE PLAYERS 352
16.7.4 PARTICIPANTS 352
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 354
16.7.5.1 Company footprint 354
16.7.5.2 Region footprint 355
16.7.5.3 Product footprint 356
16.7.5.4 Technique footprint 357
16.7.5.5 Application footprint 358
16.7.5.6 Sample type footprint 359
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 359
16.8.1 PROGRESSIVE COMPANIES 359
16.8.2 RESPONSIVE COMPANIES 360
16.8.3 DYNAMIC COMPANIES 360
16.8.4 STARTING BLOCKS 360
16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 361
16.8.5.1 Detailed list of key startup/SME players 361
16.8.5.2 Competitive benchmarking of key startups/SMEs 361
16.9 COMPETITIVE SCENARIO 362
16.9.1 PRODUCT LAUNCHES & APPROVALS 362
16.9.2 DEALS 363

17 COMPANY PROFILES 364
17.1 KEY PLAYERS 364
17.1.1 ABBOTT LABORATORIES 364
17.1.1.1 Business overview 364
17.1.1.2 Products offered 365
17.1.1.3 Recent developments 368
17.1.1.3.1 Product launches & approvals 368
17.1.1.4 MnM view 368
17.1.1.4.1 Right to win 368
17.1.1.4.2 Strategic choices 368
17.1.1.4.3 Weaknesses and competitive threats 369
17.1.2 F. HOFFMANN-LA ROCHE LTD. 370
17.1.2.1 Business overview 370
17.1.2.2 Products offered 371
17.1.2.3 Recent developments 372
17.1.2.3.1 Deals 372
17.1.2.4 MnM view 372
17.1.2.4.1 Right to win 372
17.1.2.4.2 Strategic choices 372
17.1.2.4.3 Weaknesses and competitive threats 372
17.1.3 DANAHER CORPORATION 373
17.1.3.1 Business overview 373
17.1.3.2 Products offered 374
17.1.3.3 Recent developments 375
17.1.3.3.1 Deals 375
17.1.3.4 MnM view 375
17.1.3.4.1 Right to win 375
17.1.3.4.2 Strategic choices 376
17.1.3.4.3 Weaknesses and competitive threats 376
17.1.4 QUIDELORTHO CORPORATION 377
17.1.4.1 Business overview 377
17.1.4.2 Products offered 379
17.1.4.3 Recent developments 379
17.1.4.3.1 Product launches 379
17.1.5 SIEMENS AG 380
17.1.5.1 Business overview 380
17.1.5.2 Products offered 382
17.1.6 BECTON, DICKINSON AND COMPANY 383
17.1.6.1 Business overview 383
17.1.6.2 Products offered 385
17.1.6.3 Recent developments 385
17.1.6.3.1 Product approvals 385
17.1.7 BIOMÉRIEUX SA 386
17.1.7.1 Business overview 386
17.1.7.2 Products offered 387
17.1.7.3 Recent developments 388
17.1.7.3.1 Deals 388
17.1.8 THERMO FISHER SCIENTIFIC INC. 389
17.1.8.1 Business overview 389
17.1.8.2 Products offered 391
17.1.9 REVVITY, INC. 392
17.1.9.1 Business overview 392
17.1.9.2 Products offered 394
17.1.10 QIAGEN N.V. 395
17.1.10.1 Business overview 395
17.1.10.2 Products offered 396
17.1.11 MERCK KGAA 397
17.1.11.1 Business overview 397
17.1.11.2 Products offered 398
17.1.12 HOLOGIC, INC. 399
17.1.12.1 Business overview 399
17.1.12.2 Products offered 400
17.1.12.3 Recent developments 401
17.1.12.3.1 Deals 401
17.1.13 SURMODICS, INC. 402
17.1.13.1 Business overview 402
17.1.13.2 Products offered 402
17.1.13.3 Recent developments 403
17.1.13.3.1 Deals 403
17.1.14 ORASURE TECHNOLOGIES, INC. 404
17.1.14.1 Business overview 404
17.1.14.2 Products offered 405
17.1.14.3 Recent developments 405
17.1.14.3.1 Product launches & approvals 405
17.1.14.3.2 Deals 406
17.2 OTHER PLAYERS 407
17.2.1 CHEMBIO DIAGNOSTICS, INC. 407
17.2.2 DCN DIAGNOSTICS 408
17.2.3 POLYSCIENCES INC. 409
17.2.4 ABINGDON HEALTH 410
17.2.5 ORANOXIS INC. 410
17.2.6 AESKU.GROUP GMBH 411
17.2.7 BIO GROUP MEDICAL SYSTEM S.R.L. 411
17.2.8 PHARMACT GMBH 412
17.2.9 XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. 412
17.2.10 BIOPANDA REAGENTS LTD 413
17.2.11 ARTRON LABORATORIES INC. 414

18 RESEARCH METHODOLOGY 415
18.1 RESEARCH DATA 415
18.1.1 SECONDARY DATA 415
18.1.1.1 Key data from secondary sources 416
18.1.2 PRIMARY DATA 417
18.1.2.1 Primary sources 417
18.1.2.2 Key industry insights 418
18.1.2.3 Key data from primary sources 418
18.1.2.4 Breakdown of primary interviews 419
18.2 MARKET SIZE ESTIMATION 420
18.2.1 BOTTOM-UP APPROACH 420
18.2.1.1 Approach 1: Company revenue estimation approach 421
18.2.1.2 Approach 2: Presentations of companies and primary interviews 421
18.2.1.3 Approach 3: Primary interviews 421
18.2.1.4 Approach 4: Growth Forecast 421
18.2.1.5 CAGR projections 422
18.2.2 TOP-DOWN APPROACH 422
18.3 MARKET BREAKDOWN & DATA TRIANGULATION 423
18.4 RESEARCH ASSUMPTIONS 425
18.4.1 STUDY-RELATED ASSUMPTIONS 425
18.4.2 GROWTH RATE ASSUMPTIONS 425
18.5 RISK ASSESSMENT 426
18.6 RESEARCH LIMITATIONS 426

19 APPENDIX 427
19.1 DISCUSSION GUIDE 427
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 432
19.3 CUSTOMIZATION OPTIONS 434
19.4 RELATED REPORTS 434
19.5 AUTHOR DETAILS 435

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 KEY INSIGHTS AND MARKET HIGHLIGHTS 45.
FIGURE 2 GLOBAL LATERAL FLOW ASSAYS MARKET, 2024–2031 45.
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LATERAL FLOW.
ASSAYS MARKET, 2023–2026 46.
FIGURE 4 DISRUPTIVE TRENDS IMPACTING GROWTH OF LATERAL FLOW ASSAYS MARKET 47.
FIGURE 5 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN LATERAL.
FLOW ASSAYS MARKET, 2025 47.
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 48.
FIGURE 7 HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 49.
FIGURE 8 KITS & REAGENTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 49.
FIGURE 9 CLINICAL TESTING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50.
FIGURE 10 SANDWICH ASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50.
FIGURE 11 BLOOD SAMPLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51.
FIGURE 12 HOSPITALS & CLINICS SEGMENT TO COMMAND LARGEST SHARE.
DURING FORECAST PERIOD 51.
FIGURE 13 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 52.
FIGURE 14 LATERAL FLOW ASSAYS MARKET: DRIVERS, RESTRAINTS,.
OPPORTUNITIES, AND CHALLENGES 53.
FIGURE 15 LATERAL FLOW ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS 64.
FIGURE 16 LATERAL FLOW ASSAYS MARKET: SUPPLY CHAIN ANALYSIS 69.
FIGURE 17 LATERAL FLOW ASSAYS MARKET: VALUE CHAIN ANALYSIS 70.
FIGURE 18 LATERAL FLOW ASSAYS MARKET: ECOSYSTEM ANALYSIS 71.
FIGURE 19 LATERAL FLOW ASSAYS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 77.
FIGURE 20 NUMBER OF DEALS & FUNDING ACTIVITIES IN LATERAL FLOW ASSAYS MARKET 77.
FIGURE 21 PATENT ANALYSIS FOR LATERAL FLOW ASSAYS, JANUARY 2016–DECEMBER 2025 83.
FIGURE 22 MARKET POTENTIAL OF AI IN LATERAL FLOW ASSAYS MARKET 86.
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP.
THREE APPLICATIONS 95.
FIGURE 24 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 96.
FIGURE 25 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET SNAPSHOT 229.
FIGURE 26 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET SNAPSHOT 277.
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN LATERAL FLOW ASSAYS.
MARKET, 2023–2025 348.
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LATERAL FLOW.
ASSAYS MARKET (2025) 349.
FIGURE 29 EV/EBITDA OF KEY VENDORS, 2025 350.
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA.
OF KEY VENDORS, 2025 351.
FIGURE 31 LATERAL FLOW ASSAYS MARKET: BRAND/PRODUCT COMPARISON 351.
FIGURE 32 LATERAL FLOW ASSAYS MARKET: COMPANY EVALUATION MATRIX.
(KEY PLAYERS), 2025 353.
FIGURE 33 LATERAL FLOW ASSAYS MARKET: COMPANY FOOTPRINT 354.
FIGURE 34 LATERAL FLOW ASSAYS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 360.
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT, 2025 365.
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 371.
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 374.
FIGURE 38 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025) 378.
FIGURE 39 SIEMENS AG: COMPANY SNAPSHOT (2025) 381.
FIGURE 40 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025) 384.
FIGURE 41 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2025) 387.
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 390.
FIGURE 43 REVVITY, INC.: COMPANY SNAPSHOT (2025) 393.
FIGURE 44 QIAGEN N.V.: COMPANY SNAPSHOT (2025) 396.
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2025) 398.
FIGURE 46 HOLOGIC, INC.: COMPANY SNAPSHOT (2025) 400.
FIGURE 47 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 404.
FIGURE 48 LATERAL FLOW ASSAYS MARKET: RESEARCH DESIGN 415.
FIGURE 49 KEY DATA FROM SECONDARY SOURCES 416.
FIGURE 50 LIST OF PRIMARY SOURCES 417.
FIGURE 51 KEY INSIGHTS FROM INDUSTRY EXPERTS 418.
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE,.
DESIGNATION, AND REGION 419.
FIGURE 53 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 421.
FIGURE 54 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 422.
FIGURE 55 LATERAL FLOW ASSAYS MARKET: TOP-DOWN APPROACH 422.
FIGURE 56 DATA TRIANGULATION METHODOLOGY 424.
FIGURE 57 LATERAL FLOW ASSAYS MARKET: ASSUMPTION IMPACT ASSESSMENT 425.
TABLE 1 LATERAL FLOW ASSAYS MARKET: INCLUSIONS & EXCLUSIONS 42.
TABLE 2 REAL INCIDENCE OF HIV (2023) 54.
TABLE 3 POPULATION AGES 65 AND ABOVE (% OF TOTAL POPULATION), 2025 55.
TABLE 4 LIST OF COMMERCIALLY AVAILABLE SALIVA LFA PRODUCTS 58.
TABLE 5 LATERAL FLOW ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS 64.
TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 66.
TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS 67.
TABLE 8 EUROPE: MACROECONOMIC INDICATORS 67.
TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS 68.
TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS 68.
TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 68.
TABLE 12 LATERAL FLOW ASSAYS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 71.
TABLE 13 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY PRODUCTS, BY REGION, 2024–2026 (USD) 73.
TABLE 14 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 74.
TABLE 15 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 75.
TABLE 16 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 75.
TABLE 17 LATERAL FLOW ASSAYS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 76.
TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES 78.
TABLE 19 KEY PATENTS IN LATERAL FLOW ASSAYS, 2022–2026 84.
TABLE 20 KEY COMPANIES IMPLEMENTING AI IN LATERAL FLOW ASSAYS MARKET 87.
TABLE 21 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 90.
TABLE 22 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 90.
TABLE 23 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 91.
TABLE 24 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 91.
TABLE 25 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT.
AGENCIES, AND OTHER ORGANIZATIONS 91.
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%) 96.
TABLE 27 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 96.
TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 97.
TABLE 29 LATERAL FLOW ASSAYS MARKET: UNMET NEEDS IN VARIOUS.
END-USE INDUSTRIES 98.
TABLE 30 LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 102.
TABLE 31 INDICATIVE LIST OF LATERAL FLOW ASSAY KITS & REAGENTS, WITH.
AND WITHOUT ANALYZERS 103.
TABLE 32 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY REGION,.
2024–2031 (USD MILLION) 104.
TABLE 33 NORTH AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 104.
TABLE 34 EUROPE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 104.
TABLE 35 ASIA PACIFIC: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105.
TABLE 36 LATIN AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 105.
TABLE 37 LATERAL FLOW READERS OFFERED, BY COMPANY 106.
TABLE 38 LATERAL FLOW ASSAY READERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 106.
TABLE 39 LATERAL FLOW ASSAY READERS MARKET, BY REGION, 2024–2031 (USD MILLION) 107.
TABLE 40 NORTH AMERICA: LATERAL FLOW ASSAY READERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 107.
TABLE 41 EUROPE: LATERAL FLOW ASSAY READERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 107.
TABLE 42 ASIA PACIFIC: LATERAL FLOW ASSAY READERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 108.
TABLE 43 LATIN AMERICA: LATERAL FLOW ASSAY READERS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 108.
TABLE 44 DIGITAL/HANDHELD LATERAL FLOW ASSAY READERS MARKET, BY REGION,.
2024–2031 (USD MILLION) 109.
TABLE 45 NORTH AMERICA: DIGITAL/HANDHELD LATERAL FLOW ASSAY READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 109.
TABLE 46 EUROPE: DIGITAL/HANDHELD LATERAL FLOW ASSAY READERS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 110.
TABLE 47 ASIA PACIFIC: DIGITAL/HANDHELD LATERAL FLOW ASSAY READERS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 110.
TABLE 48 LATIN AMERICA: DIGITAL/HANDHELD LATERAL FLOW ASSAY READERS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 111.
TABLE 49 BENCHTOP LATERAL FLOW ASSAY READERS MARKET, BY REGION,.
2024–2031 (USD MILLION) 111.
TABLE 50 NORTH AMERICA: BENCHTOP LATERAL FLOW ASSAY READERS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 51 EUROPE: BENCHTOP LATERAL FLOW ASSAY READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 52 ASIA PACIFIC: BENCHTOP LATERAL FLOW ASSAY READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112.
TABLE 53 LATIN AMERICA: BENCHTOP LATERAL FLOW ASSAY READERS MARKET,.
BY COUNTRY, 2024–2031 (USD MILLION) 113.
TABLE 54 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE,.
2024–2031 (USD MILLION) 115.
TABLE 55 LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR SANDWICH ASSAYS,.
BY REGION, 2024–2031 (USD MILLION) 116.
TABLE 56 NORTH AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR SANDWICH ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 57 EUROPE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR SANDWICH ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 116.
TABLE 58 ASIA PACIFIC: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR SANDWICH ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 59 LATIN AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR SANDWICH ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 117.
TABLE 60 LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR COMPETITIVE ASSAYS,.
BY REGION, 2024–2031 (USD MILLION) 118.
TABLE 61 NORTH AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR COMPETITIVE ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 118.
TABLE 62 EUROPE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR COMPETITIVE ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 63 ASIA PACIFIC: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR COMPETITIVE ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 119.
TABLE 64 LATIN AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR COMPETITIVE ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 120.
TABLE 65 LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY REGION, 2024–2031 (USD MILLION) 120.
TABLE 66 NORTH AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 67 EUROPE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 68 ASIA PACIFIC: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 121.
TABLE 69 LATIN AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 122.
TABLE 70 LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 124.
TABLE 71 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE,.
2024–2031 (USD MILLION) 125.
TABLE 72 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY REGION,.
2024–2031 (USD MILLION) 125.
TABLE 73 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 125.
TABLE 74 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 75 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 126.
TABLE 76 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 127.
TABLE 77 LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2024–2031 (USD MILLION) 127.
TABLE 78 LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2024–2031 (USD MILLION) 128.
TABLE 79 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 80 EUROPE: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 128.
TABLE 81 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 82 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 129.
TABLE 83 MAJOR PRODUCTS: DENGUE TESTING 130.
TABLE 84 LATERAL FLOW ASSAYS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2024–2031 (USD MILLION) 131.
TABLE 85 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 131.
TABLE 86 EUROPE: LATERAL FLOW ASSAYS MARKET FOR MOSQUITO-BORNE DISEASES,.
BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 87 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 132.
TABLE 88 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 133.
TABLE 89 LATERAL FLOW ASSAYS MARKET FOR INFLUENZA, BY REGION,.
2024–2031 (USD MILLION) 134.
TABLE 90 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 134.
TABLE 91 EUROPE: LATERAL FLOW ASSAYS MARKET FOR INFLUENZA, BY COUNTRY,.
2024–2031 (USD MILLION) 134.
TABLE 92 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 93 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION) 135.
TABLE 94 LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS,.
BY TYPE, 2024–2031 (USD MILLION) 136.
TABLE 95 LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS,.
BY REGION, 2024–2031 (USD MILLION) 136.
TABLE 96 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 97 EUROPE: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 98 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 99 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 100 LATERAL FLOW ASSAYS MARKET FOR HIV, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 101 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR HIV, BY COUNTRY,.
2024–2031 (USD MILLION) 139.
TABLE 102 EUROPE: LATERAL FLOW ASSAYS MARKET FOR HIV, BY COUNTRY,.
2024–2031 (USD MILLION) 139.
TABLE 103 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR HIV, BY COUNTRY,.
2024–2031 (USD MILLION) 140.
TABLE 104 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR HIV, BY COUNTRY,.
2024–2031 (USD MILLION) 140.
TABLE 105 LATERAL FLOW ASSAYS MARKET FOR HPV, BY REGION,.
2024–2031 (USD MILLION) 141.
TABLE 106 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR HPV, BY COUNTRY,.
2024–2031 (USD MILLION) 142.
TABLE 107 EUROPE: LATERAL FLOW ASSAYS MARKET FOR HPV, BY COUNTRY,.
2024–2031 (USD MILLION) 142.
TABLE 108 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR HPV, BY COUNTRY,.
2024–2031 (USD MILLION) 142.
TABLE 109 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR HPV, BY COUNTRY,.
2024–2031 (USD MILLION) 143.
TABLE 110 KEY CHLAMYDIA TESTING PRODUCTS AVAILABLE WORLDWIDE 144.
TABLE 111 LATERAL FLOW ASSAYS MARKET FOR CHLAMYDIA, BY REGION,.
2024–2031 (USD MILLION) 144.
TABLE 112 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CHLAMYDIA, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 113 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CHLAMYDIA, BY COUNTRY,.
2024–2031 (USD MILLION) 145.
TABLE 114 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CHLAMYDIA, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 115 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CHLAMYDIA, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 116 LATERAL FLOW ASSAYS MARKET FOR GONORRHEA, BY REGION,.
2024–2031 (USD MILLION) 147.
TABLE 117 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR GONORRHEA,.
BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 118 EUROPE: LATERAL FLOW ASSAYS MARKET FOR GONORRHEA, BY COUNTRY,.
2024–2031 (USD MILLION) 147.
TABLE 119 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR GONORRHEA, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 120 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR GONORRHEA, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 121 LATERAL FLOW ASSAYS MARKET FOR SYPHILIS, BY REGION,.
2024–2031 (USD MILLION) 149.
TABLE 122 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 123 EUROPE: LATERAL FLOW ASSAYS MARKET FOR SYPHILIS, BY COUNTRY,.
2024–2031 (USD MILLION) 150.
TABLE 124 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 125 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION) 151.
TABLE 126 LATERAL FLOW ASSAYS MARKET FOR OTHER SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2024–2031 (USD MILLION) 152.
TABLE 127 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 128 EUROPE: LATERAL FLOW ASSAYS MARKET FOR OTHER SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 129 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR OTHER SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 130 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 131 LATERAL FLOW ASSAYS MARKET FOR HEPATITIS, BY REGION,.
2024–2031 (USD MILLION) 154.
TABLE 132 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 133 EUROPE: LATERAL FLOW ASSAYS MARKET FOR HEPATITIS, BY COUNTRY,.
2024–2031 (USD MILLION) 155.
TABLE 134 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 135 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 136 LATERAL FLOW ASSAYS MARKET FOR TUBERCULOSIS, BY REGION,.
2024–2031 (USD MILLION) 157.
TABLE 137 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR TUBERCULOSIS,.
BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 138 EUROPE: LATERAL FLOW ASSAYS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 139 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 140 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR TUBERCULOSIS,.
BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 141 LATERAL FLOW ASSAYS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 159.
TABLE 142 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 143 EUROPE: LATERAL FLOW ASSAYS MARKET FOR OTHER INFECTIOUS DISEASES,.
BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 144 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 145 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 146 LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2024–2031 (USD MILLION) 161.
TABLE 147 LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY REGION, 2024–2031 (USD MILLION) 162.
TABLE 148 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 149 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 150 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 151 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 152 LATERAL FLOW ASSAYS MARKET FOR TROPONIN I & T TESTING, BY REGION, 2024–2031 (USD MILLION) 164.
TABLE 153 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR TROPONIN I & T TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 154 EUROPE: LATERAL FLOW ASSAYS MARKET FOR TROPONIN I & T TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 155 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR TROPONIN I & T TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 156 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR TROPONIN I & T TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 157 LATERAL FLOW ASSAYS MARKET FOR CK-MB TESTING, BY REGION,.
2024–2031 (USD MILLION) 166.
TABLE 158 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CK-MB TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 159 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CK-MB TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 160 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CK-MB TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 161 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CK-MB TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 162 LATERAL FLOW ASSAYS MARKET FOR BNP & NT-PROBNP TESTING, BY REGION, 2024–2031 (USD MILLION) 168.
TABLE 163 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR BNP & NT-PROBNP TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 164 EUROPE: LATERAL FLOW ASSAYS MARKET FOR BNP & NT-PROBNP TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 165 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR BNP & NT-PROBNP TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 166 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR BNP & NT-PROBNP TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 167 LATERAL FLOW ASSAYS MARKET FOR MYOGLOBIN TESTING, BY REGION,.
2024–2031 (USD MILLION) 171.
TABLE 168 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR MYOGLOBIN TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 169 EUROPE: LATERAL FLOW ASSAYS MARKET FOR MYOGLOBIN TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 170 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR MYOGLOBIN TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR MYOGLOBIN TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 172 LATERAL FLOW ASSAYS MARKET FOR D-DIMER TESTING, BY REGION,.
2024–2031 (USD MILLION) 173.
TABLE 173 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR D-DIMER TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 174 EUROPE: LATERAL FLOW ASSAYS MARKET FOR D-DIMER TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 175 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR D-DIMER TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 176 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR D-DIMER TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 177 LATERAL FLOW ASSAYS MARKET FOR OTHER CARDIAC MARKER TESTING,.
BY REGION, 2024–2031 (USD MILLION) 175.
TABLE 178 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER CARDIAC MARKER TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 179 EUROPE: LATERAL FLOW ASSAYS MARKET FOR OTHER CARDIAC MARKER TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 180 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR OTHER CARDIAC MARKER TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 181 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER CARDIAC MARKER TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 182 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2024–2031 (USD MILLION) 178.
TABLE 183 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING,.
BY REGION, 2024–2031 (USD MILLION) 178.
TABLE 184 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 185 EUROPE: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 186 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 187 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 188 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE 181.
TABLE 189 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY TESTING, BY REGION,.
2024–2031 (USD MILLION) 181.
TABLE 190 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 191 EUROPE: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 192 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 193 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 194 LATERAL FLOW ASSAYS MARKET FOR FERTILITY TESTING, BY REGION,.
2024–2031 (USD MILLION) 184.
TABLE 195 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR FERTILITY TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 196 EUROPE: LATERAL FLOW ASSAYS MARKET FOR FERTILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 197 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR FERTILITY TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 198 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR FERTILITY TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 199 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE 186.
TABLE 200 LATERAL FLOW ASSAYS MARKET FOR CHOLESTEROL/LIPID TESTING,.
BY REGION, 2024–2031 (USD MILLION) 186.
TABLE 201 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CHOLESTEROL/.
LIPID TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 202 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CHOLESTEROL/LIPID TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 203 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CHOLESTEROL/LIPID.
TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 204 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CHOLESTEROL/LIPID TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 205 LATERAL FLOW ASSAYS MARKET FOR DRUGS-OF-ABUSE TESTING, BY REGION, 2024–2031 (USD MILLION) 189.
TABLE 206 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 207 EUROPE: LATERAL FLOW ASSAYS MARKET FOR DRUGS-OF-ABUSE TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 208 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR DRUGS-OF-ABUSE TESTING,.
BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 209 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 210 LATERAL FLOW ASSAYS MARKET FOR OTHER CLINICAL TESTS, BY REGION,.
2024–2031 (USD MILLION) 191.
TABLE 211 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER CLINICAL TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 212 EUROPE: LATERAL FLOW ASSAYS MARKET FOR OTHER CLINICAL TESTS,.
BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 213 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR OTHER CLINICAL TESTS,.
BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 214 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER CLINICAL TESTS,.
BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 215 LATERAL FLOW ASSAYS MARKET FOR VETERINARY DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 194.
TABLE 216 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR VETERINARY DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 217 EUROPE: LATERAL FLOW ASSAYS MARKET FOR VETERINARY DIAGNOSTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 218 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR VETERINARY DIAGNOSTICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 219 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR VETERINARY DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 220 LATERAL FLOW ASSAYS MARKET FOR FOOD & ENVIRONMENT TESTING,.
BY REGION, 2024–2031 (USD MILLION) 196.
TABLE 221 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR FOOD & ENVIRONMENT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 222 EUROPE: LATERAL FLOW ASSAYS MARKET FOR FOOD & ENVIRONMENT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 223 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR FOOD & ENVIRONMENT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 224 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR FOOD & ENVIRONMENT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 225 LATERAL FLOW ASSAYS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING, BY REGION, 2024–2031 (USD MILLION) 199.
TABLE 226 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR DRUG DEVELOPMENT.
& QUALITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 227 EUROPE: LATERAL FLOW ASSAYS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 228 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 229 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR DRUG DEVELOPMENT.
& QUALITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 230 LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 202.
TABLE 231 LATERAL FLOW ASSAYS MARKET FOR BLOOD SAMPLES, BY REGION,.
2024–2031 (USD MILLION) 203.
TABLE 232 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR BLOOD SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 233 EUROPE: LATERAL FLOW ASSAYS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 234 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR BLOOD SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 235 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR BLOOD SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 236 LATERAL FLOW ASSAYS MARKET FOR URINE SAMPLES, BY REGION,.
2024–2031 (USD MILLION) 205.
TABLE 237 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR URINE SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 238 EUROPE: LATERAL FLOW ASSAYS MARKET FOR URINE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 239 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR URINE SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 240 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR URINE SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 241 LATERAL FLOW ASSAYS MARKET FOR SALIVA SAMPLES, BY REGION,.
2024–2031 (USD MILLION) 207.
TABLE 242 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR SALIVA SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 243 EUROPE: LATERAL FLOW ASSAYS MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 244 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR SALIVA SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 245 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR SALIVA SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 246 LATERAL FLOW ASSAYS MARKET FOR OTHER SAMPLES, BY REGION,.
2024–2031 (USD MILLION) 210.
TABLE 247 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 248 EUROPE: LATERAL FLOW ASSAYS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 210.
TABLE 249 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR OTHER SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 250 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR OTHER SAMPLES,.
BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 251 LATERAL FLOW ASSAYS MARKET, BY END USER, 2024–2031 (USD MILLION) 213.
TABLE 252 LATERAL FLOW ASSAYS MARKET FOR HOSPITALS & CLINICS, BY REGION,.
2024–2031 (USD MILLION) 214.
TABLE 253 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 254 EUROPE: LATERAL FLOW ASSAYS MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 255 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 256 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR HOSPITALS & CLINICS,.
BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 257 LATERAL FLOW ASSAYS MARKET FOR HOME CARE SETTINGS, BY REGION,.
2024–2031 (USD MILLION) 217.
TABLE 258 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR HOME CARE SETTINGS,.
BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 259 EUROPE: LATERAL FLOW ASSAYS MARKET FOR HOME CARE SETTINGS,.
BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 260 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR HOME CARE SETTINGS,.
BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 261 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR HOME CARE SETTINGS,.
BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 262 LATERAL FLOW ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 219.
TABLE 263 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 219.
TABLE 264 EUROPE: LATERAL FLOW ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES,.
BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 265 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 266 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 221.
TABLE 267 LATERAL FLOW ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 222.
TABLE 268 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR PHARMACEUTICAL.
& BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 222.